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Background: Breast carcinoma with choriocarcinomatous features (BCCF) is a rare variant of breast cancer,
characterized by high expression of human chorionic gonadotropin (HCG) in cancer cells such as multinucleated
syncytiotrophoblast-like giant cells. The first case of BCCF was reported in 1981 by Saigo and Rosen. Only one case
of BCCF was reported to show no component of breast ductal carcinoma, and only partially cancer cells, such as
multinucleated syncytiotrophoblast-like giant cells, expressed HCG in all previous BCCF cases. Here, we report the first
BCCF case without any component of breast ductal carcinoma in which HCG was found to express in all cancer cells.
Case presentation: A 32-year-old female patient presented with a small lump in her left breast 3 years prior. The
mass was clinically suspected to be breast infiltrating ductal carcinoma based on breast excisional biopsy and
magnetic resonance imaging findings. Due to rupture and bleeding of the left kidney, the left kidney excisional
biopsy was performed. After a retrospective analysis of the initial excised breast cancer and breast cancer metastatic to
the kidney, the cancer cells were positive for HCG by immunohistochemistry, and multinucleated or mononucleated
giant cells resembled syncytiotrophoblastic and cytotrophoblastic cells which could be seen in a background of poor
differentiated breast carcinoma and extensive necrosis and hemorrhage in the lesion. Thus, a final diagnosis of BCCF
and BCCF metastatic to the kidney was made. After combination of surgical resection (the affected left breast and left
kidney wereremoved) and consecutive chemotherapy consisting of docetaxel, epirubicin, cisplatin, lobaplatin, and
capecitabine, the patient achieved favorable therapeutic efficacy (the HCG level returned to normal values, the
metastatic lesions in the lungs disappeared, and the survival was 37 months). Capecitabine was very efficient and highly
recommended due to its superior efficacy in reducing the HCG level and eliminating the metastatic lesions in the lungs.
Conclusions: This is the first report of a rare case of BCCF without any component of breast ductal carcinoma, featured
by high expression of HCG in all cancer cells. Combination of surgery and chemotherapy (especially capecitabine)
achieved a favorable therapeutic efficacy.
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Breast carcinomas can produce various hormones normally
not secreted by the breast, including human chorionic go-
nadotropin (HCG), human placental lactogen (HPL), adre-
nocorticotropic hormone (ACTH), and norepinephrine
[1,2]. HCG has been detected in the serum in 12% to 33%
of patients with breast carcinomas [3]. However, histologic* Correspondence: jiaosc2009@126.com; yangjl301@163.com
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unless otherwise stated.examination of cancer did not reveal any evidence of
choriocarcinomatous differentiation, nordid the clinical
examination suggest any other source of HCG [2-4].
Breast carcinoma with choriocarcinomatous features
(BCCF) is a rare variant of breast carcinoma and was
first reported by Saigo and Rosen in 1981 [4]. BCCF is
characterized by HCG-expressing highly atypical cancer
cells morphologically similar to choriocarcinoma cells
admixed with a malignant epithelial and/or mesenchy-
mal component [5]. Most cases of BCCF have shown
breast-infiltrating ductal carcinoma or ductal carcin-
oma in situ with choriocarcinomatous features [3,5].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Zhu et al. World Journal of Surgical Oncology 2014, 12:239 Page 2 of 7
http://www.wjso.com/content/12/1/239Only one case of BCCF showed no component of breast
ductal carcinoma [6]. In all previous BCCF cases, only some
cancer cells, such as multinucleated syncytiotrophoblast-
like giant cells, expressed HCG [3,5]. Here, we report a
rare case of BCCF without any component of breast
ductal carcinoma, featured by high expression of HCG
in all cancer cells.
In this case report, the history, physical examination,
laboratory findings, imaging studies, and pathological
findings of BCCF in a 32-year-old woman are described
and previous literatures about BCCF are reviewed.
Case presentation
A 32-year-old woman, gravida 2 and para1, withregular
menstruation, detected a small lump of 2 × 1.5 cm in her
left breast upon self-examination in July 2010. The
breast ultrasound confirmed the presence of a 1.8 × 1.2
cm lump of low echo-levels in August 2010. In January
2011, the position emission tomography-computer tom-
ography (PET-CT) of the whole body revealed that there
were metabolism-elevating occupying lesions in the left
breast, left kidney, and two lungs. Computed tomog-
raphy (CT) confirmed the occupying lesions in the lung
and left kidney (Figure 1A,B). The core needle biopsy in
the left breast was performed, but no cancer cells were
detected. The levels of human chorionic gonadotropin
(HCG) was 22,931 U/L (normal values: 0–5 U/L). In
February 2011, the breast excisional biopsy was per-
formed and a diagnosis of breast infiltrating ductal car-
cinoma was made. In the chemotherapy regimen, one
cycle was 21 days. Two cycles of docetaxel (75 mg/m2,
once per cycle) combined with epirubicin (75 mg/m2,
once per cycle) reduced the lesions in the lungs and kid-
ney and the HCG level (5,773 U/L at the end of the first
cycle but 9,026 U/L at the end of the second cycle),
while new lesions appeared in the lungs. The chemother-
apy regimen was then changed to two cycles of docetaxel
(75 mg/m2, once per cycle) and cisplatin (75 mg/m2, once
per cycle), and the lesions in the lungs remained stable;
the HCG level continued to decrease to 1,490 U/L at the
end of the regimen. During this regimen, resection of the
left kidney was performed due to rupture and bleeding.
The left kidney excisional biopsy was also performed andFigure 1 CT (computed tomography) imaging of the lung and kidney
(BCCF) metastatic to the lung (A) and left kidney (B). The metastatic lesion
disappeared after a further 9 cycles of capecitabine.a diagnosis of high-level infiltrating renal carcinoma
(breast cancer metastatic to the kidney) was made. The
chemotherapy regimen was changed to one cycle of
docetaxel (75 mg/m2, once per cycle) and lobaplatin
(35 mg/m2, once per cycle), and the HCG level continued
to decrease to 57.86 U/L at the end of the regimen. Due to
the severe marrow depression of docetaxel and lobaplatin,
the chemotherapy regimen was changed to three cycles
of docetaxel (75 mg/m2, once per cycle) and capecita-
bine (2 g/m2) (one cycle means once-daily administra-
tion for 2 weeks followed by 1 week of rest). At the end
of the regimen, the HCG level continued to decrease to
17.64 U/L and the lesions in the lungs remained stable.
A single capecitabine was then used instead of doce-
taxel and capecitabine. After two cycles of capecitabine
(2 g/m2, one cycle means once-daily administration for
2 weeks followed by 1 week of rest), the HCG level
continued to decrease to 0.12 U/L as didthe lesions in
the lungs. The excised breast cancer and breast cancer
metastatic to the kidney were retrospectively analyzed
using HCG immunohistochemistry (IHC) staining. The
IHC results demonstrated that all the cancer cells strongly
expressed HCG, and the final pathological diagnosis was
corrected to BCCF and BCCF metastatic to the kidney
(Figures 2 and 3). After a further 9 cycles of capecitabine
(2 g/m2, one cycle means once-daily administration for 2
weeks followed by 1 week of rest), the HCG level returned
to normal values and the lesions in the lungs disappeared
(Figure 1C). At this time, the patient was still alive (the
survival was 37 months), and was undergoing her 26th
cycle of capecitabine (2 g/m2, one cycle means once-daily
administration for 2 weeks followed by 1 week of rest)
with no additional treatment.
Pathologic findings
Grossly, the left breast of the patient was normal and
BCCF did not protrude through the skin surface. The
BCCF was 3.2 × 3.2 × 1.8 cm in size, and was a solid,
well-circumscribed, and dark red mass, with extensive
necrosis and hemorrhage in the lesion. The BCCF meta-
static to the kidney was 5 × 3.5 × 2 cm in size, and was a
solid, well-circumscribed, and chromatic mass, with ex-
tensive necrosis and hemorrhage in the lesion.of the patient. Breast carcinoma with choriocarcinomatous features
s are indicated with black arrows. (C) The lesions in the lungs
Figure 2 Histology of breast carcinoma with choriocarcinomatous features (BCCF). (A) Hematoxylin-eosin (HE) staining at a low magnification.
The BCCF showed well-demarcated borders with extensive hemorrhage (the BCCF is indicated with black lines), and no infiltrating ductal carcinoma
and ductal carcinoma in situ found. Error bars represent 100 μm. (B) Hematoxylin-eosin (HE) staining at a high magnification. A sheet-like arrangement
of oval-shaped epithelial cells with prominent nucleoli was seen. Multinucleated giant cells (indicated by black arrows) with oval nuclei, prominent
multiple nucleoli, and irregular chromatin clumping resembling syncytiotrophoblastic cells could be also be seen. Error bars represent 50 μm.
(C) Immunohistochemistry (IHC) of human chorionic gonadotropin (HCG) demonstrates that all the cancer cells show strong HCG staining.
Error bars represent 50 μm.
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ders with extensive hemorrhage, and no infiltrating
ductal carcinoma and ductal carcinoma in situ could be
found (Figure 2A). At high magnification, a sheet-like ar-
rangement of oval-shaped epithelial cells with prominent
nucleoli was seen. Multinucleated giant cells with oval
nuclei, prominent multiple nucleoli, and irregular chro-
matin clumping resembling syncytiotrophoblastic cells
could also be seen (Figure 2B). The BCCF metastatic to
the kidney showed a very similar pattern in histology
(Figure 3A,B). The cancer (presented as a thin border of
intact choriocarcinoma) was well-circumscribed and cys-
tic, surrounded by normal renal tissue, with extensive
hemorrhage around it (Figure 3A). In the background
of hemorrhage, giant cells with prominent pleomorphic
nuclei, and abundant acidophilic and vacuolated cyto-
plasm resembling cytotrophoblastic cells could be seen
(Figure 3B). In all, the BCCF and BCCF metastatic to
the kidney were made up of proliferation of large sized
cells with high nucleus/cytoplasm ratio and increased
nuclear chromatin. Multinucleated or mononucleated
giant cells resembling syncytiotrophoblastic and cyto-
trophoblastic cells could be seen. This finding wasFigure 3 Histology of breast carcinoma with choriocarcinomatous fea
staining at a low magnification. The BCCF metastatic to the kidney (presen
lines) is well-circumscribed and cystic, surrounded by normal renal tissue, w
(B) HE staining at a high magnification. In the background of hemorrhage, gi
and vacuolated cytoplasm resembling cytotrophoblastic cells could be se
chorionic gonadotropin (HCG) demonstrates that all the cancer cells showsimilar to choriocarcinoma originating from genital
tract. No subtypes of breast infiltrating ductal carcin-
oma or ductal carcinoma were identified in the cancer.
No lymphovascular invasion was identified.
IHC staining was performed on paraffin-embedded tis-
sue sections, using a standard avidin-biotin-peroxidase
complex method. The IHC staining demonstrated that
all the cancer cells strongly expressed HCG in the BCCF
and BCCF metastatic to the kidney (Figures 2C and 3C).
In BCCF, other IHC markers were described as follows:
HER-1 (++); HER-2 (−); p53(−); Cyclin D1 (−); ER (−);
Ki-67 (+ >75%); PR (−); Top-IIα (+50% to 75%); p120 (++);
CK5 (−); CK7 (+); CK20 (−); CK (+); EMA (+); and
GCDFP-15 (+). In BCCF metastatic to the kidney, other
IHC markers were described as follows: HER-2 (−); ER
(−); Ki-67 (+ >75%); PR (−); CK (+); CK7 (+); CK20 (−);
EMA (+); p63 (−); Vimentin (−), and PLAP (−).
According to the IHC study findings, the diagnosis of
BCCF and BCCF metastatic to the kidney was confirmed.
Discussion
BCCF is a rare variant of breast cancer, characterized by
high expression of HCG in cancer cells such astures (BCCF) metastatic to the kidney. (A) Hematoxylin-eosin (HE)
ted as a thin border of intact choriocarcinoma, indicated with black
ith extensive hemorrhage around it. Error bars represent 100 μm.
ant cells with prominent pleomorphic nuclei, and abundant acidophilic
en. Error bars represent 50 μm. (C) Immunohistochemistry of human
strong HCG staining. Error bars represent 50 μm.
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The origin of BCCF is not clear. Some researchers sug-
gested that osseous and/or sarcomatoid metaplasia usu-
ally occurs in the development of breast infiltrating
ductal carcinoma [3]. If metaplasia occurs in the breast
infiltrating ductal carcinoma expressing HCG, the breast
infiltrating ductal carcinoma cells will show choriocarci-
nomatous features [3]. Since the first BCCF was reported
in 1981 by Saigo and Rosen [4], there have been 18 cases
of BCCF reported (including thecase in our current
study). Only one case of BCCF was reported to have no
component of breast ductal carcinoma [6]. Furthermore,
only partially cancerous cells, such as syncytiotropho-
blastic cells or cytotrophoblastic cells-like giant cells,
expressed HCG in all previous BCCF cases [3,5]. In our
case of BCCF, no component of breast ductal carcinoma
could be found, and HCG was found to be expressed in
all cancer cells.
We summarized the characteristics of all the 18 cases
in Table 1 and Table 2. In the 18 cases, the age of all pa-
tients ranged from 22 to 71 years (the average age is
46.5 years) and most tumors were located in the right
breast (13/18), although several tumors were also located
in the left breast (5/18); our patient presented with left-
breast tumors only. The tumors ranged from 1 to 10 cm,
and the metastatic tumors had the same histology as the
primary tumors. Most cases (16/18) of BCCF presented
with breast ductal carcinoma, whereas only two cases
presented with no breast ductal carcinoma, including one
case reported by Hematiet al. [6] and the case in ourTable 1 Summary of reports in literature
Patient Age (years) Localization Size (cm) LN
1 32 L 3.2 –
2 38 R 5 44/44
3 50 R 7 0/20
4 32 R / /
5 56 R 3.5 –
6 38 R 1.0 /
7 54 R 10 –
8 59 R 2.5 4/19
9 48 R 2.5 0/16
10 58 R 4 12/19
11 49 R 1.6 –
12 55 L 2.5 –
13 71 R 2.5 20/21
14 22 L 4 /
15 53 L 3.5 0/10
16 50 R 4 0/19
17 31 L / /
18 41 R 3 3study. The pathological feature of BCCF is similar to that
of choriocarcinoma in the female genital tract [5,7]. The
cytopathologic characteristics of BCCF were hemorrhagic
necrosis in the background and multinucleated bizarre
giant cells resembling syncytiotrophoblasts in the chorion.
Another characteristic is a sheet-like arrangement of oval-
shaped epithelial cells with prominent nucleoli considered
to be intermediate trophoblasts. The positive HCG stain-
ing contributes to the diagnosis of BCCF. The pathological
feature of BCCF in our case is similar to that reported by
Hematiet al. [6]; both cases presented with poor differenti-
ated carcinoma, with no component of breast ductal car-
cinoma or other types of breast cancer, extensive necrosis
and hemorrhage in the lesion, and multinucleated or
mononucleated giant cells resembling cytotrophoblastic
cells or syncytiotrophoblastic cells could be seen. The per-
centage of HCG-positive cancer cells varied in all the 18
cases. Murata et al. reported that the percentage of HCG-
positive cancer in all cancer cells was estimated to be 2%
to 3% [7], whereas a percentage of ~30% was also reported
by Resetkova et al. [8]. In Hematiet al.’s case, only some-
cancer cells were found to express HCG [6]. It is note-
worthy that, in our case, approximately 100% of the
cancer cells expressed HCG. However, the mechanism
underlying the high expression of HCG in our case re-
mains to be elucidated.
The diagnosis of BCCF is difficult, and should be dis-
criminated from many other diseases. Initially, the first
differential diagnoses were metastatic choriocarcinoma
to the breast and poor differentiated anaplastic breast-IDC-DCIS HCG HPL CK HER-2 Reference
– + / + – Present study
+ + / + / [7]
+ + / + / [9]
/ + / / / [10]
+ + / + / [11]
– + / + – [8]
+ + / + – [8]
– + + + + [3]
+ + + + + [3]
+ + + + – [3]
+ + + + – [3]
+ + / / / [4]
Mucoid + / / / [12]
+ + / / / [13]
+ + / / + [14]
+ + / / – [14]
+ + / + – [15]
– + / / / [5]
Table 2 Summary of reports in literature (continued)
Patients ER PR Ki-67 EMA PLAP P53 Follow-up Metastasis Treatment References
1 – – + + – – DFS Lung, kidney S + C Present study
2 – – / + + / Died Lung, chest wall, liver S + C + R + E [7]
3 + – / / / / / No S [9]
4 / / / / / / Died Left parietal lobe C + R [10]
5 – + + / – / DFS No S [11]
6 – – / 100 / / DFS No S + C [8]
7 – – / / / / Died Back neck, Pelvis, lungs S + C [8]
8 – – + 17 / – Lost / S + C + R [3]
9 – – + 40 / + DFS No S + C + R [3]
10 + – – 10 / + DFS No S + C + R [3]
11 – – – 2 / – Lost / S [3]
12 / / / / / / Died Lung, Lymph nodes S [4]
13 / / / / / / DFS Lymph nodes S + E [12]
14 / / / / / / / Lungs, skin C [13]
15 – – +80% / / – DFS No S [14]
16 – – +80% / / + DFS No S [14]
17 – – / / / / / / S + C [15]
18 / / / / / / Died Lung, Liver, Kidneys C [5]
“+”, Positive; “–”, Negative; “/”, Unknown. “Lost”, Lost to follow-up.
L, Left breast; R, Right breast; LN, Lymph node status; IDC-DCIS, Infiltrating ductal carcinoma-ductal carcinoma in situ; HPL, Human placental lactogen; HCG, Human
chorionic gonadotropin; CK, Cytokeratin; ER, Estrogen receptor; PR, Progesterone receptor; EMA, Epithelial membrane antigen; PALP, Placental alkaline
phosphatase; DFS, Disease free survival; S, Surgery; C, Chemotherapy; R, Radiotherapy; E, Endocrine therapy.
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static choriocarcinoma to the breast are pregnant and
have a definite history of reproductive system tumors,
and primary breast cancer could not be present in the
breast cancer. However, acomponent of primary breast
cancer, such as breast-infiltrating ductal carcinoma and/
or ductal carcinoma in situ, could be commonly found
in BCCF. Further, a positive staining of GCDFP-15 in
BCCF also supports that BCCF is a primary breast can-
cer [10,13]. Although our case presented with a compo-
nent of poor differentiated carcinoma without any
component of breast ductal carcinoma, other evidence
supports the diagnosis of BCCF: an immunohistochemi-
cal profile of GCDFP-15 (+), CK7 (+), CK20 (−), CK (+),
CK5(−), EMA (+), 32-year-old female with regular men-
struation and no history of reproductive system tumors,
and no pregnancy during disease occurrence. Thus, our
case should be diagnosis as BCCF. Furthermore, the dif-
ferential diagnosis with poor differentiated anaplastic
infiltrating ductal carcinomas mainly depends on the
positive staining of HCG [5]. Another differential diag-
nosis is the primary renal tumor expressing HCG (usu-
ally high stage renal transitional-cell carcinoma), a very
rare form of renal tumor [16]. However, in our case, no
component of transitional-cell carcinoma was discov-
ered, HCG was found to be expressed in both breast and
kidney cancer, both of which showed a very similarpattern in histology. Further, animmunohistochemical
profile of CK7 (+), CK20 (−), CK (+), and PLAP (−) in
kidney cancer was found, supporting a diagnosis of the
BCCF metastatic to the kidney.
BCCF is a highly malignant breast cancer with a poor
prognosis. Most patients die from multiple metastases
within a few months [7,8]. However, two of four patients
reported by Erhan et al. were disease-free 2 and 4 years
after diagnosis, respectively [3], and BCCF patients who
were disease-free 1 year after surgery have also been re-
ported [6,10]. The etiology behind the poor prognosis of
BCCF still remains to be elucidated, although a possible
mechanism is described as follows: pregnancy-associated
proteins such as HCG act as immunosuppressive re-
agents, and make cancer cells in BCCF invade the im-
mune defense of the host immune system, causing
BCCF to become a highly invasive cancer [17-19]. The
patient in our case underwent resection of both BCCF
and BCCF metastatic to the kidney, and the serum level
of HCG is normal. Thus, HCG might not play an immu-
nosuppressing role in the presentcase.
Current therapeutic strategies for BCCF mainly consist
of endocrine therapy, surgery, and chemotherapy. So far,
most cases of BCCF presented with double negative
staining of estrogen and progesterone (our case also pre-
sented with double negative staining of estrogen and
progesterone), whereas only one case was estrogen-
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Tamoxifen-based endocrine therapy was ineffective in
treating BCCF patients, whereas other endocrine therap-
ies, such as gonadotropin-releasing hormone analogues,
are also ineffective [5,7,12]. In all, there has not been ef-
fective endocrine therapy towards BCCF so far. Surgery
is generally considered to be effective in treating BCCF.
Although there are BCCF patients who presented with
multiple metastases and a short survival period after sur-
gery [7,10], the BCCF patients who had a disease-free
survival period of more than 1 year all underwent surgi-
cal resection [3,8,9,14]. The two patients reported by
Erhan et al. who were disease-free 2 and 4 years after
diagnosis also underwent surgical resection [3]. The
chemotherapy in BCCF regimen still remains unclear
[5,8,15]. Fluorouracil or etoposide, methotrexate, vincris-
tine, and doxorubicin are reported to be effective in treat-
ing BCCF [7,10], whereas methotrexate, actinomycin D,
and cyclophosphamide are reported to be ineffective [13].
Several studies suggested that BCCF patients received post-
operative chemotherapy but their efficacy was not reported
[3,8]. For the BCCF patients who could not receive surgery,
chemotherapy has proved both effective [10] and ineffective
[13]. In our case, the combination of surgery and chemo-
therapy was used in treating BCCF, achieving a favorable
therapeutic efficacy (the HCG level returned to normal
values, the metastatic lesions in the lungs disappeared, and
the survival was 37 months). In our chemotherapy regimen,
capecitabine may play an important role in achieving favor-
able therapeutic efficacy. The reason why capecitabine
exerts superior therapeutic efficacy towards BCCF is de-
scribed as follows. In common chemotherapy regimens for
the treatment of choriocarcinoma, 5-fluorouracil is recog-
nized as an effective drug, and capecitabine is an oral pro-
drug of 5-fluorouracil [20,21]. In the tumor, capecitabine is
selectively activated and exertsa therapeutic effect towards
tumors [21]. Thus, capecitabine may also exert a superior
therapeutic efficacy towards BCCF, which is breast carcin-
oma with choriocarcinomatous features.
Thus, combination of surgery and chemotherapy (espe-
cially capecitabine) was recommended in treating BCCF.
Conclusions
This is the first report of a rare case of BCCF without
any component of breast ductal carcinoma, featured by
a high expression of HCG in all cancer cells. A combin-
ation of surgery and chemotherapy (especially capecita-
bine) achieved favorable therapeutic efficacy (the HCG
level returned to normal values, the metastatic lesions in
the lungs disappeared, and the survival was 37 months).
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